共 281 条
[1]
Capodanno D(2018)ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison J Am Coll Cardiol. 72 2915-2931
[2]
Alfonso F(2018)2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 39 213-260
[3]
Levine GN(2016)Risks of bleeding recurrence and cardiovascular events with continued aspirin use after lower gastrointestinal hemorrhage Gastroenterology 151 271-277
[4]
Valgimigli M(2017)Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs J Gastroenterol. 52 1211-1220
[5]
Angiolillo DJ(2007)det al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants Am J Gastroenterol. 102 507-515
[6]
Valgimigli M(2019)Aspirin-free strategies after PCI: still not out of the twilight J Am Coll Cardiol. 74 2028-2031
[7]
Bueno H(2019)Ticagrelor with or without aspirin in high-risk patients after PCI N Engl J Med. 381 2032-2042
[8]
Byrne RA(2019)Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial Eur Heart J. 40 2595-2604
[9]
Collet JP(2019)Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial JAMA 321 2428-2437
[10]
Costa F(2019)Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study Platelets. 40 1-7